Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Multiple system atrophy.

G K Wenning1, F Geser

  • 1Department of Neurology, University Hospital Innsbruck, Austria. gregor.wenning@uibk.ac.at

Revue Neurologique
|May 30, 2003
PubMed
Summary
This summary is machine-generated.

Multiple system atrophy (MSA) is a rare neurodegenerative disease affecting people in their fifties. Early diagnosis of autonomic dysfunction is crucial for effective treatment, despite limited options for motor symptoms.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Monte Carlo study of a convergent X-ray beam for high resolution X-ray fluorescence imaging.

Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine·2021
Same author

Signs of early cellular dysfunction in multiple system atrophy.

Neuropathology and applied neurobiology·2020
Same author

Development of neurodegeneration in amyotrophic lateral sclerosis: from up or down?

Journal of neural transmission (Vienna, Austria : 1996)·2020
Same author

Key themes and future prospects in translational multiple system atrophy research.

Autonomic neuroscience : basic & clinical·2017
Same author

Sniffing the diagnosis: Olfactory testing in neurodegenerative parkinsonism.

Parkinsonism & related disorders·2016
Same author

Review: Multiple system atrophy: emerging targets for interventional therapies.

Neuropathology and applied neurobiology·2016
Same journal

Geographic disparities in MRI features of ischemic stroke and small vessel disease: A comparative study between French Guiana and mainland France. Findings from the BECATOUR multicenter registry.

Revue neurologique·2026
Same journal

Continuous subcutaneous perfusion of apomorphine in Parkinson's disease: Towards monotherapy?

Revue neurologique·2026
Same journal

Multimodal assessment of minimally conscious state and cognitive motor dissociation in neurocritical care: A critical review.

Revue neurologique·2026
Same journal

Development of a new episodic memory assessment tool (NEM): Preliminary data and clinical perspectives.

Revue neurologique·2026
Same journal

Novel variants and rare clinical presentations in MFN2-related Charcot-Marie-Tooth disease: Insights from 10 families.

Revue neurologique·2026
Same journal

Current management and treatment of patients with myasthenia gravis in France: A survey of the neurologist's perspective.

Revue neurologique·2026
See all related articles

Area of Science:

  • Neuroscience
  • Neurology
  • Pathology

Background:

  • Multiple system atrophy (MSA) is a sporadic neurodegenerative disorder with a mean survival of 9 years.
  • Clinical presentation includes autonomic/urogenital failure, parkinsonism (MSA-P), or cerebellar ataxia (MSA-C).
  • Pathology involves neuronal degeneration and alpha-synuclein aggregates in glial cytoplasmic inclusions.

Purpose of the Study:

  • To highlight the clinical and pathological characteristics of MSA.
  • To emphasize the importance of early diagnosis and effective treatment of autonomic dysfunction.
  • To underscore the need for further research into MSA etiology, pathogenesis, diagnosis, and therapeutics.

Main Methods:

  • Clinical case review and pathological analysis of MSA patients.

Related Experiment Videos

  • Review of current pharmacological treatments for motor and autonomic features.
  • Analysis of research initiatives addressing unmet needs in MSA.

    • Main Results:

    • Motor features in MSA have disappointing treatment outcomes, with only transient L-Dopa response in some MSA-P patients.
    • Autonomic and urogenital features of MSA can be effectively treated if identified early.
    • Significant disability and progressive nature of MSA necessitate further research.

    Conclusions:

    • Early identification and management of autonomic/urogenital symptoms are vital for improving MSA patient outcomes.
    • Current treatments for motor symptoms are largely ineffective, highlighting a critical unmet need.
    • Collaborative research efforts are essential to advance understanding and treatment of this devastating disorder.